A review based on a quick and heavily compromised cost-effectiveness evaluation conducted in secret with a threat to delist unless the company accepted a significant price reduction. Apparently, this is what constitutes a pricing negotiation in 2019. …
Latest Video
New Stories
-
New leadership for Gilead Australia and NZ
June 18, 2019 - - Latest News -
Emerging companies dominate new therapies
June 18, 2019 - - Latest News -
Patients welcome new pain national strategy
June 18, 2019 - - Latest News -
Australian 'Patient Voice Initiative' highlighted at international conference
June 18, 2019 - - Latest News -
Pfizer to acquire Array BioPharma
June 18, 2019 - - Latest News -
Bluebird Bio confirms price of its first gene therapy
June 17, 2019 - - Latest News -
Where will the government find the billions for new listings?
June 17, 2019 - - Latest News